Trial Profile
Phase I trial of MGN 1331 to test the safety and immunogenicity , a DNA vaccine for prevention of leishmaniasis.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2012
Price :
$35
*
At a glance
- Drugs MGN 1331 (Primary)
- Indications Leishmaniasis
- Focus Adverse reactions
- 28 Jun 2012 New trial record